In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor

Hypertension

Volumn 35, Issue 6, 2000, Pages 1226-1231

  Azizi, Michel ^a   Massien, Christine ^a   Michaud, Annie ^b   Corvol, Pierre ^b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b l'alimentation et l'Environnement   (France)

Author keywords

AcSDKP; Angiotensin converting enzyme; Angiotensin converting enzyme inhibitors; Human

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; OMAPATRILAT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HYPERTENSION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034097941     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.35.6.1226     Document Type: Article

References (20)

1. Wei L, Alhenc-Gelas F, Corvol P, Clauser E. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem. 1991;266:9002-9008.
2. Jaspard E, Wei L, Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II): studies with bradykinin and other natural peptides. J Biol Chem. 1993;268:9496-9503.
3. Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA, Erdos EG. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension. 1998;31:912-917.
4. Rousseau A, Michaud A, Chauvet MT, Lenfant M, Corvol P. The hemo-regulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem. 1995;270:3656-3661.
5. Wei L, Clauser E, Alhenc-Gelas F, Corvol P. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem. 1992;267:13398-13405.
6. Michaud A, Williams TA, Chauvet MT, Corvol P. Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I. Mol Pharmacol 1997; 51:1070-1076.
7. Cushman DW, Cheung MS. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 1971;20:1637-1648.
8. Nussberger J, Brunner D, Keller I, Brunner HR. Measurement of converting enzyme activity by antibody-trapping of generated angiotensin II: comparison with two other methods. Am J Hypertens. 1992;5:393-398.
9. Perish RB, Jackson B, Johnston CI. Measurement of angiotensin converting enzyme. In: Robertson JIS, Nicholls MG, eds. The Renin-Angiotensin System. Vol 1. London, UK: Gover Medical Publishing; 1993: 16.11-16.17.
10. Gros C, Noël N, Souque A, Schwartz JC, Danvy D, Plaquevent JC, Duhamel L, Duhamel P, Lecomte JM, Bralet J. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci USA 1991;88: 4210-4214.
11. Robl JA, Sun CQ, Stevenson J, Ryono DE, Simpkins LM, Cimarusti MP, Dejneka T, Slusarchyk WA, Chao S, Stratton L, Misra RN, Bednarz MS, Asaad MM, Cheung HS, Abboa-Offei BE, Smith PL, Mathers PD, Fox M, Schaeffer TR, Seymour AA, Trippodo NC. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as ' inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem. 1997;40:1570-1577.
12. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens. 1998;11:363-372.
13. Massien C, Azizi M, Guyene TT, Vesterqvist O, Mangold B, Menard J. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans. Clin Pharmacol Ther. 1999;65:448-459.
14. Waeber B, Zanchetti A, Black HR, Weber MA, Chang PI, Reeves RA, Cooper W, Moulton K, Pouleur H. Omapatrilat, a vasopeptidase inhibitor, is an effective antihypertensive agent in mild to moderate hypertension. J Hypertens. 1999;17(suppl 3):S152. Abstract.
15. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, Corvol P, Menard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl- proline. J Clin Invest. 1996;97:839-844.
16. Azizi M, Ezan E, Reny JL, Wdzieczak-Bakala J, Gerineau V, Ménard J. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans. Hypertension. 1999;33:879-886.
17. Deddish PA, Jackman HL, Skidgel RA, Erdos EG. Differences in the hydrolysis of enkephalin congeners by the two domains of angiotensin converting enzyme. Biochem Pharmacol. 1997;53:1459-1463.
18. Dive V, Cotton J, Yiotakis A, Michaud A, Vassiliou S, Jiracek J, Vazeux G, Chauvet MT, Cuniasse P, Corvol P. RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc Natl Acad Sci USA. 1999;96: 4330-4335.
19. Azizi M, Chatellier G, Guyene TT, Murieta-Geoffroy D, Ménard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation. 1995;92:825-834.
20. Junot C, Menard J, Gonzales MF, Michaud A, Corvol P, Ezan E. In vivo assessment of captopril selectivity of angiotensin I-converting enzyme inhibition: differential inhibition of acetyl-ser-asp-lys-pro and angiotensin I hydrolysis. J Pharmacol Exp Ther. 1999;289:1257-1261.